Covaxin’s Phase 3 trial data which has shown 77.8% efficacy was approved by the Subject Expert Committee (SEC) under DCGI on Tuesday.
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.